Catalyst Wire Dossier Catalyst Wire Dossier

Mektovi (binimetinib)

binimetinib · Ipsen
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Mektovi (binimetinib), covering 2025-08-01 to 2025-08-21. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [Phase 1]

See pricing